MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03395nam a22004457a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
201006s20202020 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
2590-1516 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1016/j.conx.2020.100037 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
PMC7484538 [pmc] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
S2590-1516(20)30020-4 [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
32954250 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis. [Review] |
| 251 ## - Source |
|---|
| Source |
Contraception: X. 2:100037, 2020. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Contracept X. 2:100037, 2020. |
| 253 ## - Journal Name |
|---|
| Journal name |
Contraception: X |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2020 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2021 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
epublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2020-10-06 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Background: Mifepristone and misoprostol are recommended for second-trimester medical abortion, but consensus is unclear on the ideal regimen. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Conclusion: Our analysis supports the use of mifepristone 200mg 1 to 2 days before misoprostol 400 mcg vaginally every 3h at >= 12weeks' gestation. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Data sources: We searched PubMed, Popline, Embase, Global Index Medicus, Cochrane Controlled Register of Trials and International Clinical Trials Registry Platform from January 2008 to May 2017. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Implications: Where available, providers should use mifepristone plus misoprostol for second-trimester medical abortion. Vaginal misoprostol appears to be most efficacious with fewest side effects, but sublingual and buccal routes are also acceptable. Copyright (c) 2020 World Health Organization; licensee Elsevier. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Limitations: Direct comparisons of buccal misoprostol to sublingual or vaginal routes after mifepristone were limited. Evidence from clinical trials on how to best manage women with prior uterine incisions was lacking. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Objectives: The objectives were to systematically review randomized controlled trials (RCTs) investigating efficacy, safety and satisfaction of medical abortion at >= 12weeks' gestation. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Results: We included 43 of the 1894 references identified. Combination mifepristone-misoprostol had lower rates of OP [risk ratio (RR) 0.12, 95% confidence interval (CI) 0.04-0.35] vs. misoprostol only. A 24-h interval between mifepristone and misoprostol had lower OP rate at 24h than simultaneous dosing (RR 3.13, 95% CI 1.23-7.94). Every 3-h dosing had lower OP rate at 48h (RR 0.39, 95% CI 0.17-0.88). |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Study appraisal and synthesis methods: After extracting prespecified data and assessing risk of bias in accordance with the Cochrane handbook, we used Revman5 software to combine data and GRADE to assess certainty of evidence. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Study eligibility participants and interventions: We included RCTs on medical abortion at >= 12weeks' gestation using mifepristone and/or misoprostol. We excluded studies with spontaneous abortion, fetal demise and mechanical cervical ripening and those not reporting ongoing pregnancy (OP). |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Washington Hospital Center |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Obstetrics and Gynecology |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Brant, Ashley |
| 790 ## - Authors |
|---|
| All authors |
Brant A, Fonhus MS, Ganatra B, Lavelanet A, Whitehouse K |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1016/j.conx.2020.100037">https://dx.doi.org/10.1016/j.conx.2020.100037</a> |
| Public note |
https://dx.doi.org/10.1016/j.conx.2020.100037 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
